Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 70Carcinoma, Hepatocellular 4Carcinoma, Renal Cell 3Prostate Adenocarcinoma 2Ovarian Neoplasms 2Neoplasms 2Carcinoma, Adenoid Cystic 2Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Stage II Prostate Adenocarcinoma 1Prostatic Diseases 1Prostate-specific Membrane Antigen 1Prostate Cancer Metastatic 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Esophageal Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Lobular 1Breast Neoplasms 1Biochemically Recurrent Prostate Carcinoma 1Adenocarcinoma 1

Interventions

Magnetic Resonance Spectroscopy 2prednylidene 1gallium 68 PSMA-11 1deltacortene 1apalutamide 1Prednisone 1Gonadotropin-Releasing Hormone 1BAY 86-7548 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Stage II Prostate Adenocarcinoma × gallium 68 PSMA-11 × Clear all
NCT02678351 2022-03-04

68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery

Stanford University

Phase 2/3 Completed
74 enrolled 9 charts
Genitourinary

Stage II Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡